Phase 1
Completed N=33
Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405
Hypertension(HTN)
Source: ClinicalTrials.gov NCT02387554 ↗
Enrolled (actual)
33
Serious AEs
0.9%
Results posted
Jun 2015
Primary outcomePrimary: AUClast — 1.0360; 1.1606; 1.0266; 1.0902 Ratio(Comb/Alone)
Summary
The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY AUClast |
1.0360; 1.1606; 1.0266; 1.0902 | — |
| PRIMARY Cmax |
— | — |
| SECONDARY AUCinf |
— | — |
| SECONDARY Tmax |
— | — |
| SECONDARY T1/2 |
— | — |
| SECONDARY CL/F |
— | — |
| SECONDARY Vz/F |
— | — |
Eligibility Criteria
Inclusion Criteria
- 19~45 years old
- Healthy men
Exclusion Criteria
- Gastroentestinal disease affecting drug absorption
Data sourced from ClinicalTrials.gov (NCT02387554). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.